|

Tarlatamab Clinical Trials

14 actively recruiting trials across 7 locations

Also known as: AMG 757, AMG-757, AMG757, Anti-DLL3 x Anti-CD3 BiTE AMG 757, BiTE Antibody AMG 757 +5 more

Pipeline

Phase 1: 3Phase 2: 6Phase 3: 3Phase 1/2: 2

Top Sponsors

Amgen5
University of Arizona1
University Health Network, Toronto1
Memorial Sloan Kettering Cancer Center1
Intergroupe Francophone de Cancerologie Thoracique1

Indications

Cancer14
Lung Cancer10
Extensive Stage-small Cell Lung Cancer3
Small Cell Lung Cancer3
Limited Stage Small Cell Lung Cancer2

Other6 trials

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Phase 1/2

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Phase 2

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Phase 2

Study of How Safe and Effective Tarlatamab is in Brain Cancers

Phase 2

Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

Phase 2

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Phase 3

Los Angeles, California2 trials

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Valkyrie Clinical Trials

Phase 3

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

University of Southern California, Norris Comprehensive Cancer Center

Phase 1

Gilbert, Arizona1 trial

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Banner MD Anderson Cancer Center

Phase 1

Tucson, Arizona1 trial

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Arizona Cancer Center at UMC North/University Medical Center

Phase 1/2

Jonesboro, Arkansas1 trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Saint Bernards Medical Center

Phase 3

Irvine, California1 trial

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

City of Hope Orange County Lennar Foundation Cancer Center

Phase 1

San Diego, California1 trial

A Study of Tarlatamab for People With Prostate Cancer

UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)

Phase 2

Columbus, Ohio1 trial

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.